Award Number: DAMD17-98-1-8484

TITLE: Phase I NXX3.1 in Prostate

PRINCIPAL INVESTIGATOR: Edward P. Gelmann, M.D.

CONTRACTING ORGANIZATION: Georgetown University
Washington, DC 20007-2197

REPORT DATE: January 2001

TYPE OF REPORT: Final, Phase I

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are
those of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.
**REPORT DOCUMENTATION PAGE**

**Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0740-0188), Washington, DC 20503.**

1. AGENCY USE ONLY (Leave blank)
2. REPORT DATE
   January 2001
3. REPORT TYPE AND DATES COVERED
   Final, Phase I (1 Jul 98 – 31 Dec 00)
4. TITLE AND SUBTITLE
   Phase I NXX3.1 in Prostate Cancer
5. FUNDING NUMBERS
   DAMD17-98-1-8484

6. AUTHOR(S)
   Edward P. Gelmann, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
   Georgetown University
   Washington, DC 20007-2197
   E-Mail: gelmann@georgetown.edu

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
   U.S. Army Medical Research and Materiel Command
   Fort Detrick, Maryland 21702-5012

10. SPONSORING / MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES
   This report contains colored photos

12a. DISTRIBUTION / AVAILABILITY STATEMENT
   Approved for Public Release; Distribution Unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT (Maximum 200 Words)

   We have isolated a prostate-specific gene, NXX3.1, that maps to chromosome 8p21, a common region for loss of heterozygosity in human prostate cancer. NXX3.1 is a homeobox gene that is expressed at high levels in adult human prostate. Deletion of NXX3.1 in the mouse has suggested that NXX3.1 has a suppressor effect on prostatic epithelial cell growth, and that haploinsufficiency is sufficient to produce epithelial hyperplasia. Inconsistent with the interpretation that NXX3.1 is a classical tumor suppressor gene, the coding region of NXX3.1 is not mutated in human prostate cancer. We have generated an antibody highly specific for NXX3.1. Using this reagent we have shown that loss of NXX3.1 expression is increasingly likely with prostate tumor progression. This loss of expression ranges from 16% of radical prostatectomy specimens to 80% in metastases. We have shown that a genetic polymorphism (NXX3.1 R52C) that changes DNA-binding properties of the NXX3.1 protein is present in approximately 10% of the human population. We have not found a difference in the frequency of NXX3.1 R52C between Caucasians and African Americans. The polymorphism is a risk factor for aggressive prostate cancer (high grade or high stage) (RR=1.8, 95%CI = 1.01-3.22).

14. SUBJECT TERMS
   Prostate Cancer

15. NUMBER OF PAGES
   13

16. PRICE CODE
   Unlimited

17. SECURITY CLASSIFICATION OF REPORT
   Unclassified

18. SECURITY CLASSIFICATION OF THIS PAGE
   Unclassified

19. SECURITY CLASSIFICATION OF ABSTRACT
   Unclassified

20. LIMITATION OF ABSTRACT
   Unlimited

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102
# Table of Contents

- Cover .................................................................................................................
- SF 298 ..............................................................................................................
- Introduction ....................................................................................................... 3
- Body ................................................................................................................ 3
- Key Research Accomplishments ....................................................................... 6
- Reportable Outcomes ...................................................................................... 6
- Conclusions ...................................................................................................... 7
- References ....................................................................................................... 7
- Appendices ...................................................................................................... 7
Introduction

We have isolated a prostate-specific gene, NXX3.1, that maps to chromosome 8p21, a common region for loss of heterozygosity in human prostate cancer. NXX3.1 is a homeobox gene. The mRNA is expressed at high levels in adult human prostate, at very low levels in testis and in no other tissues (1,2). Expression of NXX3.1 is androgen-regulated (1). Moreover, mice either heterozygous or homozygous for deletion of NXX3.1 had prostatic hyperplasia and an elevated growth fraction of prostatic epithelial cells (2). This implied that NXX3.1 has a suppressor effect on prostatic epithelial cell growth, and that haploinsufficiency was sufficient to produce epithelial hyperplasia. Inconsistent with the interpretation that NXX3.1 is a classical tumor suppressor gene, the coding region of NXX3.1 is not mutated in human prostate cancer (3). However, disruption of a single allele or diminished expression of NXX3.1 may occur in human prostate cancer and contribute to prostate neoplasia. We previously had reported that the human population had a polymorphism in NXX3.1 that changed amino acid 52 from arginine to cysteine (R52C) to generate a variant protein (3). The polymorphism disrupts a consensus phosphorylation sequence and abrogates dependence of DNA binding on phosphorylation in vitro. This provided a basis for asking about the role of R52C in prostate cancer risk.

Body

The approved Statement of Work had five aims. This Statement of Work anticipated a budget of $125,000. The project was funded at 75% of the requested support level. This progress report is organized under headings of each of the aims of the original Statement of Work.

Aim 1: Mutational analysis of the NXX3.1 promoter region

The original human genomic clone of NXX3.1 contained 1.3 kb of 5’ untranslated region. We found this region to have little or no transcriptional activity when placed upstream from a luciferase reporter construct. We spent much of the last year cloning a putative 5’ UTR from a phage λ human genomic DNA library. However, nucleotide sequencing of nearly 16 kb revealed that there was no overlap with the 1.3 kb of known 5’ untranslated NXX3.1 sequence. Since this information is relatively recent, we have no further progress to report on this part of Aim 1.

In addition to promoter mutation, a second potential mechanism for regulation of NXX3.1 expression in human tissues and tumors is promoter methylation. To begin to assess the role that gene methylation may play in NXX3.1 expression, we studies the effect of 5-azacytidine (5-AC), a methylase inhibitor, on the expression of NXX3.1 in prostate cancer cells. 5-AC has a complex effect on the expression of NXX3.1 in LNCaP cells (Figure 1). At 24 hours 1μM markedly increased expression. At 48 hours of treatment both 1 and 5 μM increased expression. However after 72 hours of treatment expression of NXX3.1 in LNCaP cells returned to baseline. We are continuing to study the regulation of NXX3.1 by methylation and are examining the effect of 5-AC in prostate cancer cell lines that do not express NXX3.1.

| Figure 1 |
| Effect of 5-Azacytidine on NXX3.1 Expression |

| Hr: | 24 | 48 | 72 |
|------------------|------------------|------------------|
| 5-AC (μM): | 0 | 1 | 5 | 0 | 1 | 5 | 0 | 1 | 5 |
| LNCaP |

Aim 2: NXX3.1 R52C polymorphism in racial groups and in prostate cancer patients and controls

Using the Taqman assay described in our proposal we determined NXX3.1 genotype in a cohort of 558 men with prostate cancer from the Physicians Health Study and 695 age-matched controls. The results for the total study population shown in Table 1 show no statistically significant difference between the two groups.
When we analyzed only men who presented with aggressive prostate cancer defined as stage C or D or Gleason score ≥ 7, we found a statistically significant increase in the frequency of NNX3.1 R52C among the cases, RR=1.8 (CI = 1.01-3.22). No differences between cases and controls were found for nonaggressive cancers or those men with unknown stage and grade.

Table 1

Relative risk of prostate cancer according to the CGC→TGC polymorphism of NNX3.1

<table>
<thead>
<tr>
<th>NNX3.1 genotype</th>
<th>No. Cases (%)</th>
<th>No. Controls (%)</th>
<th>RR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>499 (89.4)</td>
<td>637 (91.7)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>57 (10.2)</td>
<td>55 (7.9)</td>
<td>1.32</td>
<td>0.90-1.95</td>
</tr>
<tr>
<td>TT</td>
<td>2 (0.4)</td>
<td>3 (0.4)</td>
<td>0.85</td>
<td>0.14-5.11</td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>1.30</td>
<td>0.89-1.90</td>
</tr>
<tr>
<td>Nonaggressive Cancer a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>234 (90.4)</td>
<td>285 (89.6)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>25 (9.7)</td>
<td>31 (9.8)</td>
<td>0.98</td>
<td>0.56-1.71</td>
</tr>
<tr>
<td>TT</td>
<td>0</td>
<td>2 (0.6)</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>0.92</td>
<td>0.53-1.60</td>
</tr>
<tr>
<td>Aggressive Cancer a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>229 (88.8)</td>
<td>313 (93.4)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>27 (10.5)</td>
<td>21 (6.3)</td>
<td>1.76</td>
<td>0.97-3.19</td>
</tr>
<tr>
<td>TT</td>
<td>2 (0.8)</td>
<td>1 (0.3)</td>
<td>2.73</td>
<td>0.25-30.33</td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>1.80</td>
<td>1.01-3.22</td>
</tr>
<tr>
<td>Unknown Aggressiveness</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>36 (87.8)</td>
<td>39 (92.9)</td>
<td>1.00</td>
<td>Reference</td>
</tr>
<tr>
<td>CT</td>
<td>5 (12.2)</td>
<td>3 (7.1)</td>
<td>1.81</td>
<td>0.40-8.10</td>
</tr>
<tr>
<td>TT</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>CT+TT</td>
<td></td>
<td></td>
<td>1.81</td>
<td>0.40-8.10</td>
</tr>
</tbody>
</table>

aAggressive cancer were those cases identified at presentation as stages C or D or Gleason score ≥7.
Since the Physicians Health Study cohort was composed mostly of Caucasians, we have used a smaller cohort from Richard Hayes, PhD, of the National Cancer Institute, to determine the racial distribution of the NNX3.1 R52C polymorphism (4). The data shown in Table 2 demonstrate that there are no differences in the frequency of the NNX3.1 R52C variant protein between African Americans and Caucasians.

Table 2

<table>
<thead>
<tr>
<th>RACE</th>
<th>NNX3.1 Genotype - Nucleotide 154</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C/C</td>
</tr>
<tr>
<td>White</td>
<td>116 (87.9%)</td>
</tr>
<tr>
<td>Black</td>
<td>103 (90.35%)</td>
</tr>
<tr>
<td>Total</td>
<td>219 (89.0%)</td>
</tr>
</tbody>
</table>

**Aim 3: Immunohistochemical detection of NNX3.1 protein in prostate cancer tissues.**

We generated a rabbit antiserum to recombinant human NNX3.1 protein. The antiserum was used to study expression of NNX3.1 in normal human tissues and prostate cancer. This work has been published and is included as an appendix to this report (5). Among normal human tissues, NNX3.1 expression was seen in testis, in rare pulmonary mucous glands, and in isolated regions of transitional epithelium of the ureter. NNX3.1 was uniformly expressed in nuclei of normal prostate epithelial cells in 61 histologic sections from radical prostatectomy specimens. We analyzed 507 samples of neoplastic prostate epithelium, most of which were contained on a tissue microarray that contained samples from different stages of prostatic neoplasia. We observed complete loss of NNX3.1 expression in 5% of benign prostatic hyperplasia, 20% of high-grade prostatic intraepithelial neoplasia, 6% of T1a/b samples, 22% of T3/4 samples, 34% of hormone-refractory prostate cancer, and 78% of metastases. Our data show that NNX3.1 expression is highly, but not exclusively, specific for the prostate. Loss of NNX3.1 expression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate cancer (p < 0.0001).

**Aim 4: Identify the effect of NNX3.1 expression on prostate cancer phenotype in cultured cells**

We have transfected NNX3.1 expression vectors into TSU-Pr1 human prostate cancer cells. We saw no effect of NNX3.1 expression on in vitro cell growth or morphology of TSU-Pr1 cells. A growth curve is shown in Figure 2. Interestingly, the cells are not indifferent to the expression of NNX3.1 since in the absence of continuous antibiotic selective pressure, the NNX3.1 expression plasmid is lost. In the future as part of phase II of this project, we will examine the effect of NNX3.1 on the growth of TSU-Pr1 cells in nude mice. Preliminary data from our phase II project suggest that NNX3.1 affects in vivo growth probably by increasing apoptotic rate of cells expressing the gene (Figure 3). The data in Figure 3 were not generated as part of phase I. The animal experiments were not
performed with DOD funding. We have also found that in vitro NKX3.1 expression sensitizes cells to induction of cell death by physical and chemical agents. In both stably transfected and transiently transfected TSU-Pr1 cells we have found that NKX3.1 expression nearly doubles the cell death response to irradiation or okadaic acid treatment. Representative data from transient transfection experiments are shown in Figure 4. Full length NKX3.1 protein expression caused a 1.7-fold increased cell death three days after exposure to 20 Gy irradiation. Constructs that were truncated at amino acid 184 eliminated a C-terminal region that attenuated NKX3.1 transcriptional activation (6). The R52C mutation had a negative effect on activation of protein activity by deletion of the C-terminal sequence. A negative control was the gene inserted in reverse orientation in the expression vector.

Aim 5: Determine if RT-PCR for NKX3.1 can be applied to detect circulating prostate cancer cells

Expression of NKX3.1 is highly restricted in the mouse to prostatic lobes and bulbourethral gland (2). NKX3.1 expression is less tightly controlled in adult human tissues. There is a low level of expression in the testis and a faint signal on northern blots of peripheral blood mononuclear cell RNA. We tested whether NKX3.1 could be used in human blood samples to detect low levels of prostatic carcinoma cells. However, we found that with nested PCR reactions we could detect NKX3.1 sequences in the blood of normal men and women. We therefore have concluded that NKX3.1 will not be a useful marker for detection of circulating micrometastatic prostatic cells in patients with prostate cancer.

Key Research Accomplishments

- Determined frequency of NKX3.1 R52C polymorphism in the population and in cancer patients
- Showed that there NKX3.1 R52C variant is present with equal frequency in blacks and whites
- Demonstrated that NKX3.1 R52C is a risk factor for aggressive prostate cancer
- Developed a rabbit antiserum to human NKX3.1
- Demonstrated loss of NKX3.1 expression in prostate cancer increases with tumor progression
- Identified normal tissues that express NKX3.1

Reportable Outcomes

1. Funding applied for and received:

Genetic polymorphisms in prostate cancer
NIEHS ES-09888
PI – Edward Gelmann
NKK3.1 in Prostate Cancer

DOD Phase II Grant
DAMD17-98-1-8484

2. Employment or research opportunities

David Steadman, PhD
Postdoctoral fellow received funding in 1999 from the US Army prostate cancer research program for studies of the biochemistry of NKK3.1 binding to DNA.

Conclusions

This is the final report of phase I of our project NKS3.1 in Prostate Cancer. We have successfully accomplished four of the five original aims despite receiving only 75% of requested funding. We have demonstrated that NKK3.1 expression decreases during prostate cancer progression. This implies that loss of NKK3.1 expression may favor tumor progression and more aggressive cancer. A variant NKK3.1 protein NKK3.1 R52C, present in approximately 10% of the population, is a risk factor for aggressive prostate cancer. We have demonstrated a model system for the study of NKK3.1 effect on cell death in vitro. Future studies will examine the interaction between NKK3.1 and the cell death mechanism, will determine if loss of NKK3.1 expression in primary prostate cancer has prognostic significance and will readdress the control of NKK3.1 expression by promoter methylation.

References


Appendix

Loss of NKKX3.1 Expression in Human Prostate Cancers Correlates with Tumor Progression


ABSTRACT

NKKX3.1 is a prostate-specific homeobox gene located on chromosome 8p21. In the mouse, Nkx3.1 has growth-suppressive and differentiating effects on prostatic epithelium. Mutations of the coding region of NKKX3.1 were not found in human prostate cancer, failing to support the notion that NKKX3.1 was a tumor suppressor gene. To study the expression of NKKX3.1 protein in human tissues and prostate cancer, we derived a rabbit antiserum against purified recombinant NKKX3.1. Among normal human tissues, NKKX3.1 expression was seen in testis, in rare pulmonary mucous glands, and in isolated regions of transitional epithelium of the ureter. NKKX3.1 was uniformly expressed in nuclei of normal prostatic epithelial cells in 61 histological sections from radical prostatectomy specimens. We analyzed 507 samples of neoplastic prostate epithelium, most of which were contained on a tissue microarray that contained samples from different stages of prostatic neoplasia. We observed complete loss of NKKX3.1 expression in 5% of benign prostatic hyperplasia, 20% of high-grade prostatic intraepithelial neoplasia, 6% of T1ab, 22% of T3/4 samples, 34% of hormone-refractory prostate cancers, and 78% of metastases. Our data show that NKKX3.1 expression is highly, but not exclusively, specific for the prostate. Loss of NKKX3.1 expression is strongly associated with hormone-refractory disease and advanced tumor stage in prostate cancer (P < 0.0001).

INTRODUCTION

NKKX3.1 is a homeobox gene with prostate-specific expression in the adult (1). NKKX3.1 maps to chromosome 8p21, a region that undergoes LOH in ~75% of prostate cancer specimens (2–6). For this reason, NKKX3.1 was a candidate target gene for disruption by the 8p21 LOH. However, mutational analysis failed to find any tumor-specific mutations of NKKX3.1 in human prostate cancer tissues (2). NKKX3.1 has potency growth-suppressing and differentiating effects on prostatic epithelium. Mice heterozygous for targeted disruption of Nkx3.1 have abnormal prostate morphology with overgrown and dysplastic epithelium (7). Disruption of prostate epithelial morphology and dysplasia is more severe in Nkx3.1-null mice (7). The suggestion that gene dosage, and therefore the amount of protein, may be important for the growth-suppressor effects of NKKX3.1 prompted us to study its expression in human prostate cancer specimens.

This report describes the derivation of an antiserum against purified recombinant NKKX3.1 protein and the immunohistochemical expression of NKKX3.1 in normal human tissues and in prostate cancer specimens. One report of NKKX3.1 mRNA expression in human prostate cancer tissues described increased expression in prostate cancers compared with adjacent normal tissue (8). Our data examining NKKX3.1 protein expression support the opposite conclusion. We demonstrate that loss of the expression of this growth suppressor correlates with prostate tumor progression.

MATERIALS AND METHODS

Expression and Purification of NKKX3.1 Recombinant Protein. A 3′-truncated cDNA of wild-type NKKX3.1, including nucleotides 1–581 and excluding the region that coded for the COOH-terminal region of the protein downstream from the homeodomain, was inserted into pMAL-C2g vector (New England Biolabs, Waltham, MA) at the SalI and EcoRI restriction sites. Fusion plasmid was transformed into BL-21 competent cells (Stratagene, La Jolla, CA). An overnight culture of bacteria containing the fusion plasmid was induced with 0.5 mM IPTG for 2 h. MBP-NKKX fusion protein was purified by affinity chromatography with amylose resin (New England Biolabs). Purified fusion protein was cleaved with 0.05 μg of genase I (New England Biolabs) per 10 μg of fusion protein at room temperature for 24 h. Pure recombinant NKKX3.1 was purified again by DEAE ion exchange chromatography.

Production of NKKX3.1 Polyclonal Antibody. Twenty-five μg of purified NKKX3.1 recombinant protein in TiterMax adjuvant emulsion (CytRx Corporatio, Norcross, GA) were inoculated into New Zealand White rabbits. The total volume of the initial inoculation was 400 μl, and a 200-μl boost was administered 3–4 weeks later. Rabbits were test bled 3–4 weeks after the initial inoculation and after the second boost. Rabbit anti-NKKX3.1 antibody was purified by affinity chromatography by successive passes through BL-21-MBP CNBr-activated Sepharose 4B (Amersham Pharmacia Biotech, Uppsala Sweden) followed NKKX3.1 CNBr-activated Sepharose 4B.

Immunohistochemical Staining. Deparaffinized tissue sections were preheated in 10 mm sodium citrate solution for 20 min in a Black and Decker vegetable steamer. NKKX3.1 antibody diluted 1:1000 in blocking buffer (1:70 dilution of goat serum in PBS) was incubated on slides for 1 h at room temperature. Sections were then incubated with 1:200 diluted biotinylated secondary antibody (Vector Labs, Burlingame, CA) for 30 min and ABC solution (Vector Labs) for another 30 min. VIP peroxidase substrate (Vector Labs) was used to stain tissues, which were then counterstained with methyl green.

Tissues. Sections of normal human tissues were obtained from the Lombardi Cancer Center Histopathology and Tissue Shared Resource. Prostate tissue specimens for normal tissue and the 30 prostate cancers in the validation set came from the Lombardi Cancer Center Histopathology and Tumor Core Facility. These specimens were collected at the time of RP and therefore represent specimens from clinical stage I and II prostate cancers. All histological diagnoses were confirmed
by staining parallel sections with H&E. Specimens were reviewed by one of us (E.L.) for purposes of assigning Gleason grades.

**Tissue Microarrays.** The prostate tissue microarray was constructed as described previously (9). Briefly, core tissue biopsies (diameter, 0.6 mm) were taken from paraffin-embedded prostate tumors (donor blocks) and precisely arrayed into a new recipient paraffin block (35 x 20 mm) with a custom-built precision instrument (Beecher Instruments, Silver spring, MD). After the array block was constructed, multiple 4-μm sections were cut with a microtome using an adhesive-coated tape sectioning system (Instrumecics, Hackensack, NJ). Formalin-fixed and paraffin-embedded tumor and benign control specimens were obtained from the archives of the Institutes for Pathology, University of Basel (Basel, Switzerland), the Canton Institute for Pathology (Liestal, Switzerland), and the Tampere University Hospital (Tampere, Finland). The tissue microarray initially contained 632 specimens from all stages of tumor progression. The presence of tissue conforming to the histopathological category assigned in the original assembly was verified by review of an H&E-stained section within 50 μm of the section stained for NKK3.1; this review identified 477 tissue core specimens that were included in the analysis. Tissue samples included BPH as control (n = 43); primary tumors with stage T1a,b according to International Union Against Cancer criteria (10), incidentally discovered after transurethral resection for presumed BPH (n = 109); clinically localized tumors obtained from RF specimens (clinical stage T2; n = 110); primary, locally advanced tumors (clinical stage T3a,b) treated by transurethral resection (n = 27); distant metastases collected from autopsies of patients who had died from end-stage metastatic prostate cancer (n = 35); and 108 local recurrences after hormonal therapy failure, including 65 transurethral resections from living patients and 43 specimens obtained from autopsies. Tumor grading on the original tissue sections was performed according to Gleason (11). The array also included 54 cores from high grade PIN lesions; however, because of the focal nature of PIN, we verified the H&E staining of each sample on the array and identified only 20 as clearly showing high-grade PIN in the tissue core specimens on the array.

**Statistical Methods.** Specimens were available from 30 radical prostatectomies. These specimens were assessed for Gleason score and NKK3.1 expression to determine whether NKK3.1 expression differed among specimens with at least one Gleason grade ≥4 compared with those with both grades <4. The prostate tissue samples available for tissue microarray analysis were ordered by increasing disease severity for the following classifications: BPH, PIN, T1 tumors, RP specimens, and T3/T4 tumors. Specimens available from HR samples and metastatic disease represented more severe disease than the previously mentioned tissues, but their position in severity status relative to each other was unknown. Of primary interest was whether there is a decrease in NKK3.1 expression with increasing disease status. Two separate questions were addressed. The first was whether a trend in NKK3.1 expression is present with disease status BPH through T3a,b in the order listed above, with HR tumors as the most severe disease status. The second question was similar, except that metastatic disease rather than HR tumors was the most severe disease. Of additional interest was whether the combined group of T1a,b and RP tissues differed from T3a,b and whether it differed from metastatic tumors. These questions were tested using a Jonkhheere-Terpstra test as implemented in StatXact (Cytel). Unless specified below, all tests were considered significant if P was <0.05. To control for the two tests using HR or metastatic tumors as the sixth tissue type, the decrease in NKK3.1 expression was considered significant if the two-sided P was <0.025. Specific pairwise comparisons with BPH through T3a,b were performed for HR or metastatic tumors provided the overall test was significant. Similarly, the two comparisons of T1a,b with either T3a,b or metastatic tissue were considered significant for P < 0.025.

**RESULTS**

Recombinant NKK3.1 was made as an MBP fusion protein in *Escherichia coli*. Cleavage of the fusion protein with genenase yielded electrophoretically pure NKK3.1 (Fig. 1A). Antibody to MBP did not react with cleaved NKK3.1, indicating complete cleavage of NKK3.1 from the fusion protein (Fig. 1B). Rabbit antiserum derived against purified recombinant NKK3.1 reacted only with NKK3.1 on Western blot and not with either E. coli proteins or MBP (Fig. 1C). The antiserum recognized 32-kDa NKK3.1 in TSU-Pr1 cells transfected with an NKK3.1 expression plasmid, but detected no proteins in TSU-Pr1 cells because they express <1/100 the level of NKK3.1 mRNA found in LNCaP cells (Fig. 1D). The induction of NKK3.1 mRNA by androgen treatment of LNCaP cells has been described and was reflected in the induction of NKK3.1 protein after R1881 treatment of LNCaP cells (Fig. 1D; Refs. 1, 12).

The expression of NKK3.1 mRNA is restricted in the adult mouse and humans. In the mouse, expression is seen only in the prostatic lobes and the bulbourethral gland (7). Expression in humans was seen predominantly in the prostate, but low levels of mRNA were also detected in testis (1). There also appeared to be signals in peripheral blood lymphocytes (1). In fact, our attempts to use NKK3.1 as a prostate-specific marker failed because reverse transcription-PCR detected transcripts in female peripheral blood. To clarify the expression of NKK3.1 in human tissues, we did immunohistochemical staining of 16 human tissues, including prostate, brain, heart, lung, kidney, testis, bladder, ureter, skin, liver, spleen, bone marrow, small and large intestine, breast, and endometrium, using our rabbit antiserum. On the basis of preliminary studies with LNCaP cells and NKK3.1-transfected TSU-Pr1 cells, we expected to find this homeobox protein localized to the nucleus.

We detected expression of NKK3.1 in testis, confirming the results for mRNA expression (Fig. 2, A and B). We also noted expression of NKK3.1 in rare mucous glands of the lung (Fig. 2, C and D). Lastly, we found expression of NKK3.1 in groups of urethral epithelial cells periodically spaced along the lumen of the ureter (Fig. 2, E and F). Bladder transitional epithelium contained rare single cells with nu-
Fig. 2. Immunohistochemical staining of normal human tissues with anti-NKX3.1. Sections were cut in parallel and stained with either H&E (A, C, E, and G) or anti-NKX3.1 (B, D, F, and H). Images A–F were captured digitally using ×400 microscopic magnification; G and H, were captured digitally using ×63 magnification. A and B, normal testis seminiferous tubules. C and D, pulmonary mucous gland. E and F, urethral transitional epithelium. G and H, prostate gland. IHC, immunohistochemistry.

clear staining (not shown). We found no expression in tissues that contained blood cells, including bone marrow and spleen. Nonmalignant prostatic epithelial cells had uniformly positive nuclear staining for NKX3.1. This was seen in 61 RP specimens (Fig. 2, G and H).

To determine the expression of NKX3.1 in neoplastic prostate epithelium, we analyzed a tissue microarray that contained a spectrum of tissue samples providing a cross-section of prostate tumor progression. To validate the data in the array from one category of tissue, we performed conventional immunohistochemical staining on a separate set of 61 embedded tissue blocks from prostatectomy specimens. Thirty of these blocks contained malignant foci that were scored for NKX3.1 expression and compared with the results of the RP samples in the tissue microarray.

Neoplastic prostate epithelium was found to display three different patterns of immunostaining for NKX3.1 expression. Many samples stained uniformly for NKX3.1. Some samples stained heterogeneously, with some malignant cells stained and adjacent cells not stained. Some samples displayed no staining for NKX3.1. In samples in which malignant cells did not express NKX3.1, adjacent normal epithelial cells were invariably positive, providing an internal control for the quality of the specimen. The patterns of staining are shown in Fig. 3. For the purposes of analyzing the 477 microarray samples and the 30 sections, uniform staining was awarded a score of 2, heterogeneous staining a score of 1, and samples that did not stain were scored 0.

The results of staining for the tissue microarray are shown in Table 1. Whereas the majority of samples from early-stage cancers stained uniformly for NKX3.1 in epithelial cell nuclei, the number of samples with heterogeneous or negative staining increased among the locally advanced T3/T and HR samples. There was a significant reduction of NKX3.1 expression in advanced prostate cancer as defined by either HR (P < 0.0001) or metastatic disease (P < 0.0001). HR demonstrated significantly lower NKX3.1 expression than BPH (P < 0.0001), T1u (P < 0.0001), and RP (P = 0.013). Metastatic samples differed from all tissue samples BPH through T3/T (P < 0.0001 for each). The combined group of T1u tumors and RP samples had significantly higher NKX3.1 expression than metastases (P < 0.0001) but did not achieve a significant difference compared with T3/T (P = 0.06); Refs. 13, 14).

Seventy-eight percent of metastatic samples had no staining for NKX3.1. The integrity of these autopsy samples was confirmed by staining for Ki-67, which was seen to decorate nearly all of the metastatic samples. Because Ki-67 may be more stable than NKX3.1 under conditions found at autopsy, we also compared the HR speci-
However, staining of HR autopsy specimens scored positive twice as often as staining of autopsy-derived metastases.

The series of 30 RP specimens analyzed as conventional sections cut from paraffin blocks gave nearly identical results to the distribution of staining patterns found among the RP specimens in the tissue microarray. The microarray RP samples gave a nearly identical distribution of staining scores compared to these 30 paraffin block samples; therefore, the staining of conventional samples validated the tissue microarray data and confirmed that a fraction of early-stage prostate cancers lose expression of NKKX3.1.

The 30 samples from paraffin blocks were subjected to histological grading (11). In contrast to the relationship between loss of NKKX3.1 staining and prostate tumor progression, we found no relationship between NKKX3.1 staining scores and Gleason scores in the 30 RP blocks. The distribution of NKKX3.1 staining results over the range of tumor grades as measured by Gleason score is shown in Table 2. Samples were compared across all scores and compared as groups with at least one grade ≥4 versus both grades <4. There was no evidence indicating that patients with lower NKKX3.1 expression had higher Gleason scores (P = 0.611; Ref. 13).

**DISCUSSION**

Our data show that NKKX3.1 expression is lost in a significant fraction of early-stage prostate cancer and that loss of expression correlates with tumor progression. Because NKKX3.1 has differentiating and growth-suppressing effects in the mouse prostate, it is tempting to speculate that NKKX3.1 plays a tumor-suppressor function in human prostate cancer. If, similar to the mouse, the human prostatic epithelium is sensitive to the level of NKKX3.1 protein, then diminution in the level of NKKX3.1 expression, even in tissues that demonstrate heterogeneous staining, may play a role in the pathogenesis or progression of human prostate cancer. NKKX3.1 staining was found in three patterns in the tissue samples. Most samples, except for metastases, showed diffuse staining of both normal and neoplastic prostatic epithelial cells. In our experience, all normal prostate epithelial cells express NKKX3.1. NKKX3.1 expression decreases with disease severity. That fact combined with the lack of relationship between NKKX3.1 expression and the Gleason score means that NKKX3.1 expression has the potential to be a promising new prognostic marker if it is associated with patient survival. Further studies are warranted in this area.

A previous report that NKKX3.1 mRNA expression was increased in prostate cancer tissues compared with adjacent normal tissues arrived at a different conclusion from our findings (8). If the results of Xu et al. (8) are confirmed, it would lead to the conclusion that control of NKKX3.1 expression occurs at the posttranscriptional level.

In the survey of 61 tissue sections, we found no example of

---

**Table 1: Frequencies of progression array staining for NKKX3.1**

<table>
<thead>
<tr>
<th>NKKX3.1 staining score</th>
<th>Tissue microarray samples, n (%)</th>
<th>RP sections, n (%)</th>
<th>HR</th>
<th>Meta</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BPH</td>
<td>PIN</td>
<td>TI, RP</td>
<td>T3/4</td>
</tr>
<tr>
<td>2</td>
<td>36 (84)</td>
<td>9 (45)</td>
<td>83 (76)</td>
<td>68 (62)</td>
</tr>
<tr>
<td>1</td>
<td>5 (12)</td>
<td>7 (17)</td>
<td>19 (17)</td>
<td>24 (22)</td>
</tr>
<tr>
<td>0</td>
<td>2 (5)</td>
<td>4 (20)</td>
<td>7 (6)</td>
<td>18 (16)</td>
</tr>
<tr>
<td>Total (100%) tissue</td>
<td>45</td>
<td>20</td>
<td>109</td>
<td>110</td>
</tr>
</tbody>
</table>

* RP sections from tissue microarray and paraffin sections presented similar NKKX3.1 score profiles.
* Meta, metastatic disease.
* This test is significant at 0.05. No adjustment was made because these analyses were controlled by the overall test.
* This test is significant at the specified P < 0.025.
nonmalignant prostatic glands failing to stain for NKK3.1. In the array, two BPH specimens displayed no staining. We cannot state at this time whether this represents a background of tissues that failed to stain for technical reasons or a subset of prostatic hyperplasia with true loss of NKK3.1 expression. Analysis of PIN samples revealed that more than half had reduced or absent NKK3.1 expression. Therefore, NKK3.1 may also play a role in the development of prostate cancer. A larger number of PIN lesions need to be analyzed to elucidate the role of NKK3.1 in prostate cancer development.

The finding that NKK3.1 expression was lost most often in metastases is consistent with the notion that metastatic disease is the most dedifferentiated state of prostate cancer. It may also be that NKK3.1 expression is under the control of prostate stromal cells. In murine tissue recombinants of neonatal epithelium and mesenchyme from the urogenital sinus, only tissues that underwent prostatic differentiation expressed Nkx3.1 (7). On the other hand, the quality of the specimens, particularly from autopsies, could have resulted in sample degradation and diminished ability to detect NKK3.1. The mechanism of modulating NKK3.1 expression in human prostate cancer remains to be elucidated. It has not been determined whether NKK3.1 undergoes LOH in those tissues that display LOH at 8p21. Therefore, it is possible that loss of a single NKK3.1 allele as a result of LOH at 8p21 could down-regulate NKK3.1 expression. Because NKK3.1 is a differentiating protein, its expression may be regulated by gene methylation. We presently are characterizing the upstream sequences of NKK3.1 to identify regions that may be targets for gene silencing by methylation. Methylation is an important mechanism for loss of differentiated functions in human cancers such as diminished androgen-receptor expression in breast cancer (15, 16). It remains to be determined whether promoter methylation plays a role in the down-regulation of NKK3.1 expression in prostate cancer.

The survey of NKK3.1 expression in normal tissues underscores the high degree of prostate specificity in the expression pattern of this protein. The role of NKK3.1 in the function of extraprostatic cells where it is found, bronchial mucous glands, testis, and uter, is unknown. Nkx3.1 is not expressed in murine testis, and the Nkx3.1 (−/−) mice were fertile. There was no obvious ureteral or pulmonary pathology attributed to loss of Nkx3.1 in the gene-deleted mice (7). If the only apparent action of Nkx3.1 is as a prostate-specific repressor, the gene may have application in prostate-specific gene therapy. The potential for application of gene therapy to the treatment of prostate cancer is under active investigation. There may be advantages to the use of suppressor genes with limited tissue-specific effects to minimize toxicity of gene therapy to other organs. Whether ectopic expression of NKK3.1 in organs other than the prostate will have any functional ramifications remains to be shown. In addition, because of its tissue-specific expression in the adult, the NKK3.1 promoter is a potentially useful determinant for prostate-specific expression of exogenous genes. The probasin promoter has been quite useful in generating a murine prostate cancer model by driving organ-specific expression of the SV40 T antigen (17–19). Whether the Nkx3.1 promoter will have similar effects remains to be shown. Early in murine development, Nkx3.1 expression occurs in many regions of the embryo and may play a noncritical role in the development of other organs (20, 21). Lastly, the NKK3.1 promoter may have applications in tissue-specific gene therapy of prostatic disease. The expression of NKK3.1 in other tissues shown in this report will help to identify potential organs for side effects of treatments targeted to the prostate by the NKK3.1 promoter.

ACKNOWLEDGMENTS

The Lombardi Cancer Center Histopathology and Tissue Shared Resource provided normal human tissues. We are particularly grateful to Baljit Singh for assistance. Microscopy was done in the Lombardi Cancer Center Microscopy and Imaging Shared Resource.

REFERENCES